Bringing the fundamentals into focus…
Back to Vertex Pharmaceuticals Incorporated
How Vertex Pharmaceuticals Incorporated stacks up
VRTX · against 588 other Healthcare companies listed in US-listed
Valuation
55/ 100
Above the middle of the pack.
Ranked #153 of 589 · scores higher than 73% of peers
Bars: peers in each 10-point band of the valuation score57 peers with a valuation score of 50–59, including VRTX · Click a bar to see the companies
Why valuation scores 55?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 4.0% vs peer median 4.0%
- higher earnings for the price paid: stronger than 64% of peers. Earnings yield: 3.3% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 66% of peers. Free cash flow yield: 2.8% vs peer median 0.0%
Metric by metric
Position: dot = VRTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | VRTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | 3.2% | -4.3% | 80% | 30% | |
| EBITDA yieldHigher is better · 578 reported | 4.0% | -0.8% | 65% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | 2.8% | -2.3% | 70% | 20% | |
| Book yieldHigher is better · 587 reported | 15.1% | 25.9% | 34% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around VRTX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 153 | 1.6B USD | 55 | 51 | |
| 153 | 3.0B USD | 55 | 39 | |
| 153 | 48.9B USD | 55 | 54 | |
| 153 | 9.3B USD | 55 | 64 | |
| 153 | 134.5B USD | 55 | 70 | |
| 158 | 406M USD | 54 | 59 | |
| 158 | 5.8B USD | 54 | 68 | |
| 158 | 969M USD | 54 | 54 | |
| 158 | 474M USD | 54 | 46 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score